GlassScriptPhysician profile
Thomas D Selby
NPI 1679911382
$15,095.47
in general payments reported to CMS, 2019-2025
32 companies · $3,135 in 2025
The $3,135 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $14.41 · 2021: $756 · 2022: $1,791 · 2023: $5,391 · 2024: $3,832 · 2025: $3,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,906 · Consulting Fee: $2,980 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,914 · Education: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,905.91 |
| Consulting Fee | $2,980.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,913.75 |
| Education | $558.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,153.21 | 2023-2025 | Spevigo |
| Abbvie INC. | $1,814.00 | 2021-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $1,430.11 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $938.82 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $802.77 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $685.61 | 2021-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $649.65 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $423.49 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $412.60 | 2019-2025 | Sotyktu |
| Incyte Corporation | $412.04 | 2022-2025 | Opzelura |
| Genzyme Corporation | $383.76 | 2021-2025 | |
| Ucb, INC. | $360.02 | 2022-2025 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $321.42 | 2021-2025 | Tremfya |
| Leo Pharma INC. | $265.52 | 2022-2025 | Adbry, Spevigo, Anzupgo |
| Arcutis Biotherapeutics, INC. | $171.81 | 2023-2025 | Zoryve |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $153.13 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $141.01 | 2023-2025 | Cabtreo, Jublia |
| Biofrontera INC. | $122.80 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Amgen INC. | $102.72 | 2019-2025 | Otezla |
| Genentech USA, INC. | $82.87 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $41.25 | 2019 | |
| Verrica Pharmaceuticals INC. | $38.98 | 2024-2025 | Ycanth |
| Organogenesis INC. | $27.59 | 2025 | Cygnus Dual |
| Organon LLC | $26.91 | 2023-2025 | Hadlima |
| Kyowa Kirin, INC. | $23.50 | 2023 | Poteligeo |
| Botanix Sb INC | $21.26 | 2025 | Sofdra |
| Ge Healthcare | $19.11 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.80 | 2021 | |
| Dermavant Sciences, INC. | $15.07 | 2023 | Vtama |
| Krystal Biotech INC | $15.00 | 2025 | Vyjuvek |
| Reprise Biomedical, INC. | $11.91 | 2025 | Miro3d |
| Merck Sharp & Dohme LLC | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Selby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.